Return to Research Home
Immune Support / Regulation · Intelligence File

VIP

Vasoactive Intestinal Peptide, a 28 amino acid neuroimmune signaling peptide studied for immune regulation, inflammatory balance, vascular tone, and gut-lung-immune communication.

α-Helix · 14 Residues · Drag to Rotate
10 sources reviewed
01

Plain Terms

VIP stands for Vasoactive Intestinal Peptide. It is a natural signaling peptide found in the body that helps regulate communication between the nervous system, immune system, gut, lungs, blood vessels, and inflammatory pathways.

In simple terms, VIP is studied for helping the body calm excessive inflammation, support immune balance, protect barrier tissues, regulate blood vessel tone, and coordinate communication between the brain, gut, lungs, and immune system.

This is not a simple immune booster. VIP is better described as an immune-regulating and inflammation-modulating peptide. It is studied for helping the body create a more balanced immune response instead of just turning inflammation up or down.

In practical human terms, VIP is researched for immune regulation, inflammatory balance, lung and airway biology, gut barrier function, neuroimmune signaling, vascular tone, and tissue-protection pathways.

The simple way to understand VIP: it is a signaling peptide studied for helping the immune system, nervous system, gut, lungs, and blood vessels communicate more intelligently under stress.

02

Scientific Overview

Vasoactive Intestinal Peptide, commonly called VIP, is a 28 amino acid neuropeptide. Although it was first associated with the intestinal system, VIP is now known to be widely distributed throughout the body, including the central and peripheral nervous systems, gastrointestinal tract, respiratory system, cardiovascular system, endocrine system, and immune system.

VIP works mainly through VPAC1 and VPAC2 receptors, which are G protein-coupled receptors found in multiple tissues. These receptors help explain why VIP has such broad biological effects, including effects on immune cells, smooth muscle, blood vessels, epithelial tissues, hormone signaling, and inflammatory pathways.

Within Immune Support / Regulation, VIP belongs on the immune-regulation and neuroimmune communication side of the category. The immune system is constantly communicating with the nervous system, gut, lungs, hormones, blood vessels, and barrier tissues, and VIP is one of the peptides involved in that communication.

VIP has been studied for its anti-inflammatory and immunomodulatory effects. Research describes VIP as helping regulate innate immune cell function, cytokine production, macrophage activity, dendritic cell behavior, T-cell differentiation, regulatory T-cell activity, and the balance between pro-inflammatory and anti-inflammatory signaling.

This is why VIP should not be described as a blunt immune stimulant. It is more accurately described as a regulatory peptide that may help shift immune activity toward a more controlled, balanced, and tolerance-supporting state.

VIP has also been studied in autoimmune and inflammatory disease models because of its ability to influence immune tolerance and inflammatory signaling. Reviews discuss VIP's role in modulating responses in conditions such as rheumatoid arthritis, inflammatory bowel disease models, autoimmune disease models, sepsis research, and lung-inflammation research. These findings support relevance to immune regulation but do not make VIP a proven treatment for autoimmune disease.

VIP is also relevant to respiratory and lung biology. VIP receptors are found in lung tissue, and synthetic VIP, also called aviptadil, has been studied in pulmonary hypertension, acute respiratory distress syndrome, sarcoidosis, and COVID-related respiratory failure. Inhaled aviptadil research in pulmonary hypertension showed temporary pulmonary vasodilation and improved certain hemodynamic measures in a small human study.

VIP has important vascular effects. The word vasoactive means it can affect blood vessel tone. VIP is known for vasodilation, meaning it can relax blood vessels. This is one reason it is studied in pulmonary vascular disease, but it also means blood pressure, circulation, flushing, headache, dizziness, or cardiovascular sensitivity may matter in real-world safety discussions.

VIP also has gastrointestinal relevance. It is involved in gut motility, intestinal secretion, epithelial signaling, and gut immune regulation. Because the gut is a major immune organ, VIP's role in gut and mucosal immune balance is part of why it belongs in the immune support and regulation category.

03

Evidence Strength

VIP has substantial preclinical evidence for immunomodulatory and anti-inflammatory activity, with mechanistic research across immune cells, gut, lungs, and vasculature.

Human clinical research is more limited and largely focused on the synthetic VIP analogue aviptadil in specific contexts such as pulmonary hypertension, sarcoidosis (orphan designation, not approval), and COVID-related respiratory failure. Broad immune, inflammation, or wellness claims are not supported.

04

Safety & Regulatory Notes

VIP is biologically active across multiple systems, immune system, nervous system, lungs, blood vessels, and gastrointestinal tract. It should be presented as a research peptide, not a casual wellness supplement.

Potential concerns may include blood pressure changes, flushing, headache, dizziness, gastrointestinal effects, cardiovascular sensitivity, immune-system effects, and complications in people with complex inflammatory, autoimmune, cardiovascular, pulmonary, endocrine, or cancer-related conditions.

Aviptadil is a synthetic form of VIP that has received FDA orphan drug designation for certain investigational uses, including sarcoidosis. Orphan designation is not the same as FDA approval. FDA's orphan listing for aviptadil in sarcoidosis states it is not FDA approved for that orphan indication.

VIP should not be described as an FDA-approved treatment for immune support, inflammation, lung health, chronic illness, anti-aging, mold illness, autoimmune disease, or general wellness.

05

Best Use Description

VIP is a 28 amino acid neuroimmune signaling peptide studied for immune regulation, inflammatory balance, cytokine modulation, macrophage activity, dendritic cell function, regulatory T-cell activity, gut barrier signaling, lung and airway biology, vascular tone, epithelial protection, and neuroimmune communication.

06

Positioning Summary

VIP is best positioned as a research peptide involved in immune regulation, inflammatory control, vascular signaling, gut-lung-immune communication, and neuroimmune balance.

Its strongest practical relevance is the study of how the body coordinates immune activity, inflammation, mucosal barrier protection, lung signaling, gut signaling, and blood vessel response under biological stress.

The most accurate framing is immune-regulation and neuroimmune signaling research, not guaranteed immune boosting, inflammation reduction, lung repair, autoimmune treatment, mold illness treatment, anti-aging, or disease reversal.

07

Sources

Numbered citations supporting this educational writeup. External links open peer-reviewed literature, registered trials, or regulatory positions.

  1. [01]Iwasaki M, Akiba Y, Kaunitz JD. Recent Advances in Vasoactive Intestinal Peptide Physiology and Pathophysiology: Focus on the Gastrointestinal System. F1000Research. 2019.
  2. [02]Couvineau A, Laburthe M. VPAC Receptors: Structure, Molecular Pharmacology and Interaction With Accessory Proteins. British Journal of Pharmacology. 2012.
  3. [03]Delgado M, Ganea D. Vasoactive Intestinal Peptide: A Neuropeptide With Pleiotropic Immune Functions. Amino Acids. 2011.
  4. [04]Smalley SG, Barrow PA, Foster N. Immunomodulation of Innate Immune Responses by Vasoactive Intestinal Peptide. British Journal of Pharmacology. 2009.
  5. [05]Pozo D, Anderson P, Gonzalez-Rey E. Tuning Immune Tolerance With Vasoactive Intestinal Peptide: A New Therapeutic Approach for Immune Disorders. Peptides. 2007.
  6. [06]Villanueva-Romero R, Gutiérrez-Cañas I, Carrión M, et al. The Anti-Inflammatory Mediator Vasoactive Intestinal Peptide in Rheumatoid Arthritis. Frontiers in Immunology. 2018.
  7. [07]Leuchte HH, Baezner C, Baumgartner RA, et al. Inhalation of Vasoactive Intestinal Peptide in Pulmonary Hypertension. European Respiratory Journal. 2008.
  8. [08]Youssef JG, Lavin P, Schoenfeld DA, et al. The Use of IV Vasoactive Intestinal Peptide, Aviptadil, in Patients With Critical COVID-19 Respiratory Failure. Critical Care Medicine. 2022.
  9. [09]Domschke S, Domschke W, Bloom SR, et al. Vasoactive Intestinal Peptide in Man: Pharmacokinetics, Metabolic and Circulatory Effects. Gut. 1978.
  10. [10]U.S. Food and Drug Administration. Orphan Drug Designations and Approvals: Aviptadil for Treatment of Sarcoidosis.

This page is for educational and research purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Always consult a qualified medical professional before making health decisions.

Find your protocol